Microfluidics industry: how the COVID-19 lockdown reshuffled the cards
Product Related
Adoption of point-of-care and next generation sequencing technologies are propelling new microfluidics players on the market and revenues to an expected US$32 billion in 2027.
OUTLINE
The microfluidics market at the module level is expected to reach about US$32 billion in 2027.
Polymer remains the primary material for manufacturing single-use microfluidic components.
Illumina, Danaher (Cepheid), bioMerieux… the top 15 microfluidics companies control more than 82% of the microfluidics market, but new players have taken serious advantage of the emergency policies to make their own products available.
Microfluidic technologies have experienced new momentum due to the impact of the COVID-19 pandemic. Global revenues at the module level of US$18.1 billion were estimated in 2021 and are forecast to reach US$32 billion in 2027, with a good dynamic CAGR 2022-2027 reaching 10.1%. Over the last two years, microfluidic technologies have been used in various diagnostic solutions. Besides point-of-care testing, the market is driven by clinical laboratory diagnostics and pharmaceutical and life science research tools. In this context, Yole Intelligence, part of Yole Group, has developed comprehensive and in-depth medical technologies expertise for over 20 years. Throughout the year, analysts investigate this industry and deliver their analyses in an extensive collection of technology and market reports, monitors, and teardowns… More information. Thus, Yole Intelligence offers today a particular focus on the microfluidics industry with a dedicated report: Status of the Microfluidics Industry. Taking into account the impact of the COVID-19 crisis over two years, this study provides a complete analysis of microfluidic component/module applications, markets, and technologies.
Clyde Midelet, Ph.D.,
Technology & Market Analyst, Sensing and Actuating in the Photonics & Sensing division at Yole Intelligence
“We observed a huge demand for molecular tests (PCR) and immunoassays (antigenic, antibody) that are considered as gold standards for diagnostics in rapid point-of-care and high-throughput solutions. The necessity to prevent infection before transmission or detect the infection at an early stage clearly boosts and drives the microfluidic market”.
Indeed, a technological race has begun to get the easiest-to-use, most sensitive, and fastest test available on the market. DNA sequencing techniques are also driving the microfluidics market and technical innovations, showing impressive growth in several domains, such as tracking virus mutations, oncology, genomics, proteomics, single-cell analysis, and so on.
Titre du visuel
june 2021
You have to be registered to download our medias.
Usage restriction: Images may not be used against the interests of Yole Développement (Yole Group) and its entities, Yole Intelligence, or System Plus Consulting (Yole SystemPlus).
For more information, please contact the Public Relations team.
Licence
:
Images can be used online and for printing, without modification
Thematic(s)
:
Polymers are the most widely-used material for manufacturing microfluidic devices (used in 89% of them) and account for 61% of the market value. Glass and silicon devices are much more expensive and are used in specific technologies such as next-generation sequencing. Silicon is increasingly used for photonic biochip development or on-chip sensing based on CMOS technology. As in the semiconductor industry, this will bring intelligence to microfluidic modules for point-of-care devices and next-generation technologies.
A significant trend of alliances between expert microfluidics players has been observed in the microfluidics supply chain, offering a single point of entry for newcomers to develop devices based on microfluidic technologies quicker. Microfluidics represents a tremendous potential for classic semiconductor players like IDEX, SCHOTT, Xfab, Teledyne, and TE Connectivity. This brings all these fabs’ know-how into the hands of major companies that are used to working with industry leaders.
Yole Intelligence’s sensing and actuating team invites you to follow the microfluidic industry on www.yolegroup.com. Stay tuned!
Clyde Midelet, Ph.D., Technology & Market Analyst, Sensing and Actuating in the Photonics & Sensing division at Yole Intelligence“We observed a huge demand for molecular tests (PCR) and immunoassays (antigenic, antibody) that are considered as gold standards for diagnostics in rapid point-of-care and high-throughput solutions. The necessity to prevent infection before transmission or detect the infection at an early stage clearly boosts and drives the microfluidic market”.
